Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $190
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Equal-Weight rating on Biogen (NASDAQ:BIIB) but lowers the price target from $200 to $190.
August 02, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays analyst Carter Gould maintains an Equal-Weight rating on Biogen but lowers the price target from $200 to $190.
The lowered price target from $200 to $190 suggests a less optimistic outlook for Biogen's stock performance, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100